Table 1.
Drug concentration leading to a 50% inhibition of cell viability at 72 h (IC50) in cellTiterGLO® assay and Combination Index (CI) for each cell line
| MPM Cell Lines | IC50 Drug alone (95% confidence interval) | IC50 Drug combination (95% confidence interval) | CI at IC50 ± Est. st.dev* | ||
|---|---|---|---|---|---|
| Everolimus (nM) | Sorafenib (μM) | Everolimus (nM) | Sorafenib (μM) | ||
| MES-MM98 | >100 | 4.21 (2.91-6.09) | 40 (10.6-150.5) | 2 (1.03-4.02) | 0.485 ± 0.20 |
| MM001 | >100 | 2.01 (1.86-2.21) | 23.6 (14.9-37.5) | 1.18 (0.75-1.87) | 0.585 ± 0.08 |
| NCI-H226 | >100 | 2.12 (1.55-2.89) | 32 (20.5-49.9) | 1.60 (1.02-2.49) | 0.755 ± 0.23 |
| MSTO-211H | >100 | 0.90 (0.68-1.19) | 34 (33.4-35.3) | 0.17 (0.01-1.77) | 0.426 ± 0.19 |
| IST-MES1 | >100 | 1.69 (1.10-2.60) | 28.3 (17.1-46.8) | 1.42 (0.85-2.34) | 0.873 ± 0.30 |
| IST-MES2 | >100 | 2.16 (1.66-2.80) | 19.1 (9.8-37.1) | 0.96 (0.49-1.86) | 0.573 ± 0.22 |
| NCI-H28 | >100 | 3.34 (2.27-4.92) | 27 (14–51.6) | 1.36 (0.71-2.58) | 0.920 ± 0.34 |
| NCI-H2052 | >100 | 6.21 (4.45-8.66) | 44.7 (31–63.9) | 2.23 (1.56-3.19) | 0.950 ± 0.21 |
| MM002 | >100 | 2.78 (2.30-3.35) | 18.6 (6–57.2) | 0.93 (0.30-2.86) | 0.345 ± 0.12 |
*combination index calculated at IC50 ± estimated standard deviation based on Chou-Talalay method.